Company: HROW
Filing Date: 2025-09-08
Form Type: 8-K
Source: 0001493152-25-012778
Chunk: 2

Company: HARROW, INC.
Filing Date: 2025-09-08
Form: 8-K
Item: Item 2.03
Chunk 2
---
 Any offer or solicitation will be made only by means of a confidential offering memorandum. This Current Report on Form
8-K does not constitute a notice of repayment or notice of redemption of outstanding indebtedness.

Conditional
Redemption of Senior Notes due 2027

On
September 8,

The
redemption of the 2027 Notes is subject to, and conditioned upon, completion of the Offering on terms and conditions satisfactory to
the Company, the gross proceeds of which are no less than $250.0 million (the “ Redemption Condition”).

If
the Redemption Condition is satisfied, the 2027 Notes will be redeemed at a redemption price equal to 102% of the principal amount of
the 2027 Notes redeemed, plus accrued and unpaid interest to, but not including, the 2027 Note Redemption Date. If the redemption of
the 2027 Notes is consummated, the Company will fund such redemption using a portion of the proceeds from the Offering.

Expected
Redemption of Senior Notes due 2026

The
Company expects to deliver on the closing date of the Offering a notice of full redemption to the Trustee to redeem all of the Company’s
outstanding 8.625% Senior Notes due 2026 (the “2026 Notes”) pursuant to the redemption provisions of the Indenture dated
as of April 20, 2021, as supplemented by the First Supplemental Indenture dated as of April 20, 2021. The redemption date for the 2026
Notes if notice of redemption is provided would be no less than 30 days, and no more than 60 days, following the delivery of the redemption
notice to the Trustee. The 2026 Notes are listed on Nasdaq under the symbol “ HROWL” and would be delisted following redemption.

The
2026 Notes will be redeemed at a redemption price equal to 100% of the principal amount of the 2026 Notes redeemed, plus a make-whole
amount and accrued and unpaid interest to, but not including, the 2026 Note Redemption Date. If the redemption of the 2026 Notes is consummated,
the Company will fund such redemption using a portion of the proceeds from the Offering.

Potential
Acquisition of Remaining Interests in Melt Pharmaceuticals, Inc.

On
August 7, 2025, the Company entered into a non-binding indication of interest (“ IOI”) to acquire the equity interests in
Melt Pharmaceuticals,